Anthera Pharmaceuticals (ANTH) Stock Analysis & Winston Score

Winston Score History

Anthera Pharmaceuticals was a small biotechnology company focused on developing drugs to treat serious diseases, including heart disease and autoimmune conditions. Its pipeline included experimental medicines targeting inflammation and related conditions, with patients and hospitals as the end customers. The company operated in the highly competitive drug development space, where most revenue depended entirely on successfully bringing new treatments through clinical trials.

Anthera's business model relied on advancing drug candidates through trials and either commercializing them or partnering with larger pharmaceutical companies for licensing deals — meaning it generated little to no product revenue for most of its history. It was a US-based company with a small footprint and limited financial resources typical of early-stage biotechs. The company faced significant challenges after key drug candidates failed in late-stage trials, and based on its near-zero market cap and margins, it appears to have wound down or ceased meaningful operations, making its current status as a going concern the central risk.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

+88.4% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

0.2%ownership

Relatively low insider ownership

Cash Runway

~3 months

$8M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Anthera Pharmaceuticals has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-673.9%

Weak — -673.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial